I also believe it was a fine presentation, it creates a great deal of optimism for the future, and I recognize his time was limited. What I didn't hear were answers to all the questions I wish would be answered.
I understand that Israeli's like to play their hands close to the belt, and I can understand that, but I believe the stock was down today mostly because of the delay in results for the safety trial, and it would have been nice had he given us a reason for that.
That said, do I want to stay in the stock, you bet. Do I believe it will go higher this year, or is it dead money, I believe it will go higher, but primarily on new partnerships or other forms of collaborations which will open up sales throughout the world. I'm still unsure of the possibility of marketing anything this year as I'm unsure if only safety must be demonstrated, or if efficacy must be.
One thing was quite clear to me, which I had suspected before, is that the sublingual tablet will be available in many different formulations, which is as it should be. I don't know whether each formulation will require a clinical trial, or if you test essentially 3 formulations, one with max CBD, one with max THC, and one with the max of the two in combination, would you then be able to use all formulations in between. Of course another question would deal with the hundreds of other compounds found in cannabis, and do they want to try some of these in the tablet, or other products, I suspect that over time they will.
They are most certainly taking the scientific approach toward cannabis, and in time I believe most countries will welcome the benefits of true drugs developed with cannabis, whether it's legal recreational cannabis or not.
Gary
I understand that Israeli's like to play their hands close to the belt, and I can understand that, but I believe the stock was down today mostly because of the delay in results for the safety trial, and it would have been nice had he given us a reason for that.
That said, do I want to stay in the stock, you bet. Do I believe it will go higher this year, or is it dead money, I believe it will go higher, but primarily on new partnerships or other forms of collaborations which will open up sales throughout the world. I'm still unsure of the possibility of marketing anything this year as I'm unsure if only safety must be demonstrated, or if efficacy must be.
One thing was quite clear to me, which I had suspected before, is that the sublingual tablet will be available in many different formulations, which is as it should be. I don't know whether each formulation will require a clinical trial, or if you test essentially 3 formulations, one with max CBD, one with max THC, and one with the max of the two in combination, would you then be able to use all formulations in between. Of course another question would deal with the hundreds of other compounds found in cannabis, and do they want to try some of these in the tablet, or other products, I suspect that over time they will.
They are most certainly taking the scientific approach toward cannabis, and in time I believe most countries will welcome the benefits of true drugs developed with cannabis, whether it's legal recreational cannabis or not.
Gary
